<![CDATA[Isatuximab-Based Therapy Shows “Impressive” PFS Projections in NDMM]]>

Data ReadoutpositiveIsatuximabBortezomibLenalidomidePositive

AI Analysis

Summary

Analysis of the BENEFIT trial demonstrates that isatuximab combined with bortezomib, lenalidomide, and dexamethasone achieves impressive progression-free survival projections in transplant-ineligible newly diagnosed multiple myeloma patients, supporting its use as a new standard of care.

Clinical Trial Data

Primary Endpoint

Met

Outcome Details

Analysis of BENEFIT trial supports isatuximab plus bortezomib, lenalidomide, and dexamethasone showing impressive progression-free survival projections in transplant-ineligible newly diagnosed multiple myeloma

Importance:6/10

Sentiment:

0.75

oncologymultiple myelomacombination therapyclinical trialprogression-free survival

Related Companies

$SNYNF

Read the original article

Published by Cancer Network on September 27, 2026 5:00 PM

Read Original